Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

25P-NBOMe

25P-NBOMe molecule structure25P-NBOMe molecule structure
2C-P-NBOMe
NBOMe-2C-POpen in Piru
Psychoactive Class
PsychedelicHallucinogen

25P-NBOMe is a rare, potent psychedelic in the NBOMe family of phenethylamines and is a derivative of 2C-P. It produces effects similar to those of related compounds, including 25I-NBOMe and 25C-NBOMe. It was described in the scientific literature by 2012,1 first sold in mid-to-late 2012, and reappeared on the market in early 2015.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold100-250 µg
Light250-450 µg
Moderate450-700 µg
Strong700-1500 µg
Heavy1500+ µg

Duration

Onset25-40 minutes
After Effects1-16 hours
Total7-14 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

25P-NBOMe is a potent agonist at serotonin 5-HT2 receptors, including 5-HT2A.2

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMTLithiumPregabalin

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

AmphetaminesCocaineDXMTramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

No lethal-dose or LD50 data were identified. Available descriptions characterize 25P-NBOMe as a rare, potent psychedelic with risks similar to other NBOMe compounds.

History & Culture

25P-NBOMe was characterized in a 2012 scientific publication.3 It was first sold in mid-to-late 2012 and reappeared on the market in early 2015.

Legality

By Country

Illegal1
United Kingdom flagUnited KingdomIllegal

References

Source Pages

  1. Bluelight: The Small & Handy 25P-NBOMe Thread
  2. Erowid: 25P-NBOMe Experience Report
  3. Wikipedia
  4. Wikipedia: 2C-P-NBOMe

Citations

  1. Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I. Microgram Journal (2012). https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_84-109.pdf1
  2. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology (2015). https://doi.org/10.1016/j.neuropharm.2015.08.03412
  3. Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I. Microgram Journal (2012). https://forendex.southernforensic.org/uploads/references/MicrogramJournal/9.2.84.109.pdf1
  4. PubChem CID 118796470 Synonyms. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/118796470/synonyms/JSON1
  5. PubChem 25P-NBOMe Chemical Properties. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/25P-NBOMe/property/IUPACName,Title,MolecularFormula/JSON1
  6. Misuse of Drugs Act 1971, Schedule 2 Part I paragraph 1(c). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/11
  7. Misuse of Drugs Act 1971, section 2. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/21
  8. Misuse of Drugs Act 1971, section 3. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/31
  9. Misuse of Drugs Act 1971, section 4. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/41
  10. Misuse of Drugs Act 1971, section 5. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/51

Further Reading

  1. ChemSpider: 25P-NBOMe Chemical Structure Data
  2. EMCDDA: Europol (2023) - NBOMe Compounds Analytical Data
  3. Hansen et al. (2014) - Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines
  4. Luethi & Liechti (2018) - Monoamine Transporter and Receptor Interaction Profiles
  5. Zawilska et al. (2020) - NBOMes: Highly Potent and Toxic Alternatives of LSD

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25P-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.